Medical Oncology

, 32:195 | Cite as

Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer

  • Xiaoling Gu
  • Yingying Wang
  • Hua Wang
  • Qichao Ni
  • Chunhui Zhang
  • Jia Zhu
  • Wei Huang
  • Pan Xu
  • Guoxin MaoEmail author
  • Shuyun YangEmail author
Original Paper


PFTK1 was a cell division cycle 2-related serine/threonine protein kinase, which was up-regulated in breast cancer tissues and breast cancer lines. And up-regulated PFTK1 was highly associated with grade, axillary lymph node status, and Ki-67. Moreover, Kaplan–Meier curve showed that up-regulated PFTK1 was related to the poor breast carcinoma patients’ overall survival. Here, we first discovered and confirmed that cyclin B was a new interacting protein of PFTK1, and the complex might increase the amount of DVL2, which triggers Wnt/β-catenin signaling pathway. Furthermore, knockdown of PFTK1 attenuated cell proliferation, anchorage-independent cell growth, and cell migration and invasion by inhibiting the transcriptional activation of β-catenin for cyclin D1, MMP9, and HEF1, whereas exogenous expression of PFTK1 might promote MDA-MB-231 cells proliferation, migration, and invasion via promoting PFTK1–DVL2–β-catenin axis. Our findings supported the notion that up-regulated PFTK1 might promote breast cancer progression and metastasis by activating Wnt signaling pathway through the PFTK1–DVL2–β-catenin axis.


PFTK1 Breast cancer Proliferation Migration Invasion 



This study was funded by the National Natural Science Foundation of China Grants (Nos. 81302285, 81472185).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Sakharkar MK, Shashni B, Sharma K, Dhillon SK, Ranjekar PR, Sakharkar KR. Therapeutic implications of targeting energy metabolism in breast cancer. PPAR Res. 2013;2013:109285.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229–39.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, et al. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast cancer Res. 2011;13(3):R58.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Fujii S, Tokita K, Wada N, Ito K, Yamauchi C, Ito Y, et al. MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene. 2011;30(39):4118–28.PubMedCrossRefGoogle Scholar
  6. 6.
    Kong C, Wang C, Wang L, Ma M, Niu C, Sun X, et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 2011;6(7):e22666.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang L-H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67(5):1979–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer. 2010;9:162.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–205.PubMedCrossRefGoogle Scholar
  10. 10.
    Gabrovska P, Smith RA, Tiang T, Weinstein SR, Haupt LM, Griffiths LR. Development of an eight gene expression profile implicating human breast tumours of all grade. Mol Biol Rep. 2012;39(4):3879–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–20.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 2013;13(1):174.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Incassati A, Chandramouli A, Eelkema R, Cowin P. Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast cancer Res. 2010;12(6):213.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol. 2008;8(8):581–93.PubMedCrossRefGoogle Scholar
  15. 15.
    He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E2 on colon cancer cells. Cancer Res. 2010;70(2):824–31.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23(1–2):101–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H, et al. Interaction of Axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 1999;18(10):2823–35.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Yang T, Chen J. Identification and cellular localization of human PFTAIRE1. Gene. 2001;267(2):165–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Shu F, Lv S, Qin Y, Ma X, Wang X, Peng X, et al. Functional characterization of human PFTK1 as a cyclin-dependent kinase. Proc Natl Acad Sci. 2007;104(22):9248–53.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Jiang M, Gao Y, Yang T, Zhu X, Chen J. Cyclin Y, a novel membrane-associated cyclin, interacts with PFTK1. FEBS Lett. 2009;583(13):2171–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Leung W, Ching A, Chan A, Poon T, Mian H, Wong A, et al. A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene. 2011;30(44):4464–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Miyagaki H, Yamasaki M, Miyata H, Takahashi T, Kurokawa Y, Nakajima K, et al. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2012;106(5):947–54.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Yue W, Zhao X, Zhang L, Xu S, Liu Z, Ma L, et al. Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis. Clin Lung Cancer. 2011;12(1):43–50.PubMedCrossRefGoogle Scholar
  26. 26.
    Sun T, Co NN, Wong N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochem Biophys Res Commun. 2014;449(1):163–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Niehrs C, Acebron SP. Mitotic and mitogenic Wnt signalling. EMBO J. 2012;31(12):2705–13.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Liu Y, Wang Y, Cheng C, Chen Y, Shi S, Qin J, et al. A relationship between p27kip1 and Skp2 after adult brain injury: implications for glial proliferation. J Neurotrauma. 2010;27(2):361–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5):e63404.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Tao T, Cheng C, Ji Y, Xu G, Zhang J, Zhang L, et al. Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-κB activation. Mol Biol Cell. 2012;23(14):2635–44.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Liu Z, Rebowe RE, Wang Z, Li Y, Wang Z, DePaolo JS, et al. KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer. Mol Cancer Res. 2014;12(4):491–503.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Dai M, Al-Odaini AA, Fils-Aimé N, Villatoro MA, Guo J, Arakelian A, et al. Cyclin D1 cooperates with p21 to regulate TGFb-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 2013;15(3):R49.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Marastoni S, Andreuzzi E, Paulitti A, Colladel R, Pellicani R, Todaro F, et al. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration. J Pathol. 2014;232(4):391–404.PubMedCrossRefGoogle Scholar
  34. 34.
    Prasad CP, Chaurasiya SK, Axelsson L, Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol Oncol. 2013;7(5):870–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Xiaoling Gu
    • 1
    • 3
  • Yingying Wang
    • 3
  • Hua Wang
    • 4
  • Qichao Ni
    • 4
  • Chunhui Zhang
    • 4
  • Jia Zhu
    • 3
  • Wei Huang
    • 3
  • Pan Xu
    • 3
  • Guoxin Mao
    • 1
    Email author
  • Shuyun Yang
    • 2
    Email author
  1. 1.Department of OncologyAffiliated Hospital of Nantong UniversityNantongChina
  2. 2.Department of Pathology, Nantong University Cancer HospitalNantong UniversityNantongChina
  3. 3.Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Information and Molecular Drug TargetNantong UniversityNantongChina
  4. 4.Department of General SurgeryThe Affiliated Hospital of Nantong UniversityNantongChina

Personalised recommendations